Metamizol Slavia (Metamizole Sodium Monohydrate)

Metamizole sodium works by inhibiting cyclooxygenase enzymes, which lowers prostaglandin synthesis, and by modulating endogenous opioid pathways. This combination reduces the perception of pain and resets the body's temperature set‑point, providing both analgesic and antipyretic effects without strong anti‑inflammatory activity.

The exact dose of Metamizol Slavia is determined by the prescribing clinician based on the patient’s condition, age, weight, and response to therapy. Dosage regimens are individualized and should follow the prescriber’s instructions and local regulatory guidelines.

Safety data for metamizole sodium in pregnancy and lactation are limited, and the drug is generally avoided unless the potential benefit outweighs the risk. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To request Metamizol Slavia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with non‑steroidal anti‑inflammatory drugs (NSAIDs), metamizole offers strong analgesic and antipyretic effects with less gastrointestinal irritation but carries a risk of agranulocytosis. Unlike opioids, it does not produce significant respiratory depression, making it a useful alternative for certain acute pain scenarios.

Metamizol Slavia should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight, and extreme temperatures to maintain stability and potency.

Metamizol Slavia is formulated for oral administration. The tablets or oral solution are taken by mouth with water, following the prescriber’s dosing schedule. Patients should not crush or chew extended‑release forms unless specifically instructed.

The most serious adverse reaction is agranulocytosis, a potentially fatal drop in neutrophil count that can lead to severe infections. Other critical risks include anaphylaxis, severe skin reactions such as Stevens‑Johnson syndrome, and significant liver or blood‑cell toxicity. Immediate medical attention is required if these symptoms appear.

Metamizol Slavia should be avoided in patients with known hypersensitivity to pyrazolones, a history of agranulocytosis, severe liver or kidney disease, and in individuals taking other myelosuppressive agents without close monitoring. Pregnant or breastfeeding women should only use it if clearly indicated by a healthcare professional.